A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer - Concepedia

Concepedia

Publication | Closed Access

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

292

Citations

27

References

2007

Year

Michael A. Carducci, Fred Saad, Per‐Anders Abrahamsson, David P. Dearnaley, Claude C. Schulman, Scott North, Darryl J. Sleep, Jeffrey D. Isaacson, Joel B. Nelson

Abstract

Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden.

References

	Year	Citations

Page 1